Patient's perceptions of buprenorphine use receiving treatment for cancer.

Objective: To assess knowledge and attitudes toward opioids and buprenorphine (BUP) of patients with cancer.

Design: Single-site, single-intervention telephone survey of patients under palliative care at the cancer center.

Outcomes: Forty percent of the participants recognized the word "buprenorphine," and 28 percent recognized BUP indication for addiction treatment.

Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women.

Once-daily injections of teriparatide initially increase biochemical markers of bone formation and resorption, but markers peak after 6-12 months and then decline despite continued treatment. We sought to determine whether increasing teriparatide doses in a stepwise fashion could prolong skeletal responsiveness. We randomized 52 postmenopausal women with low spine and/or hip bone mineral density (BMD) to either a constant or an escalating subcutaneous teriparatide dose (30 μg daily for 18months or 20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months).

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.

Context: Teriparatide increases both bone formation and bone resorption.

Objective: We sought to determine whether combining teriparatide with an antiresorptive agent would alter its anabolic action.

Design And Setting: This was a randomized controlled trial conducted in a single university hospital.

Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.

Context: In postmenopausal women, bone mineral density (BMD) declines after teriparatide therapy is stopped. The pattern of BMD loss after teriparatide therapy is stopped in men is less clear.

Objective: The aim of the study was to determine whether the pattern of teriparatide-induced bone accrual and post-teriparatide bone loss differs between postmenopausal women and eugonadal men.

Effects of teriparatide retreatment in osteoporotic men and women.

Context: The stimulatory effect of teriparatide on bone mineral density (BMD) and bone turnover is initially exuberant, but then diminishes.

Objective: Our objective was to determine whether retreating with teriparatide after a drug-free period can restore the initial exuberant response to teriparatide.

Design And Setting: This was a planned extension of a randomized controlled trial conducted in a single university hospital.